NCT05753566View on ClinicalTrials.gov

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Prostate CancerBiochemical Recurrence
Interventions
DRUG

Rezvilutamide

Specifications of 80 mg; orally, once a day

DRUG

Androgen deprivation therapy (ADT)

Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information

RADIATION

SRT

SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)

Trial Locations (2)

210000

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

Unknown

NOT_YET_RECRUITING

JiangSu Cancer Hospital, Nanjing

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER